These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
125 related articles for article (PubMed ID: 1535251)
1. Effects of SCH 34826, a neutral endopeptidase inhibitor, on hypoxic pulmonary vascular remodelling. Stewart AG; Sheedy W; Thompson JS; Morice AH Pulm Pharmacol; 1992 Jun; 5(2):111-4. PubMed ID: 1535251 [TBL] [Abstract][Full Text] [Related]
2. Effects of the neutral endopeptidase inhibitor, SCH 42495, on the cardiovascular remodelling secondary to chronic hypoxia in rats. Thompson JS; Sheedy W; Morice AH Clin Sci (Lond); 1994 Jul; 87(1):109-14. PubMed ID: 8062513 [TBL] [Abstract][Full Text] [Related]
3. Neutral endopeptidase inhibition attenuates development of hypoxic pulmonary hypertension in rats. Klinger JR; Petit RD; Warburton RR; Wrenn DS; Arnal F; Hill NS J Appl Physiol (1985); 1993 Oct; 75(4):1615-23. PubMed ID: 8282611 [TBL] [Abstract][Full Text] [Related]
4. Neutral endopeptidase (NEP) inhibition in rats with established pulmonary hypertension secondary to chronic hypoxia. Thompson JS; Sheedy W; Morice AH Br J Pharmacol; 1994 Dec; 113(4):1121-6. PubMed ID: 7889263 [TBL] [Abstract][Full Text] [Related]
5. Neutral endopeptidase 24.11 inhibition reduces pulmonary vascular remodeling in rats exposed to chronic hypoxia. Winter RJ; Zhao L; Krausz T; Hughes JM Am Rev Respir Dis; 1991 Dec; 144(6):1342-6. PubMed ID: 1835825 [TBL] [Abstract][Full Text] [Related]
6. The neutral endopeptidase inhibitor, SCH 34826, reduces left ventricular hypertrophy in spontaneously hypertensive rats. Monopoli A; Ongini E; Cigola E; Olivetti G J Cardiovasc Pharmacol; 1992 Sep; 20(3):496-504. PubMed ID: 1279298 [TBL] [Abstract][Full Text] [Related]
7. Atrial natriuretic factor-potentiating and antihypertensive activity of SCH 34826. An orally active neutral metalloendopeptidase inhibitor. Sybertz EJ; Chiu PJ; Vemulapalli S; Watkins R; Haslanger MF Hypertension; 1990 Feb; 15(2):152-61. PubMed ID: 2154404 [TBL] [Abstract][Full Text] [Related]
8. Effects of acute and chronic blockade of neutral endopeptidase with Sch 34826 on NaCl-sensitive hypertension in spontaneously hypertensive rats. Jin H; Mathews C; Chen YF; Yang R; Wyss JM; Esunge P; Oparil S Am J Hypertens; 1992 Apr; 5(4 Pt 1):210-8. PubMed ID: 1318053 [TBL] [Abstract][Full Text] [Related]
9. Neutral endopeptidase inhibitors and the pulmonary circulation. Thompson JS; Morice AH Gen Pharmacol; 1996 Jun; 27(4):581-5. PubMed ID: 8853287 [TBL] [Abstract][Full Text] [Related]
10. Concurrent neutral endopeptidase and ACE inhibition in experimental heart failure: renal and hormonal effects. Helin K Scand J Clin Lab Invest; 1993 Dec; 53(8):843-51. PubMed ID: 8140395 [TBL] [Abstract][Full Text] [Related]
11. Reversal of pulmonary vascular remodelling following hypoxic exposure: no effect of infusion of atrial natriuretic factor and neutral endopeptidase inhibitor. Zhao L; Hughes JM; Winter RJ Cardiovasc Res; 1994 Apr; 28(4):519-23. PubMed ID: 8181040 [TBL] [Abstract][Full Text] [Related]
12. Inhibition of either angiotensin-converting enzyme or neutral endopeptidase induces both enzymes. Helin K; Tikkanen I; Hohenthal U; Fyhrquist F Eur J Pharmacol; 1994 Oct; 264(2):135-41. PubMed ID: 7851475 [TBL] [Abstract][Full Text] [Related]
13. Basal and volume expansion-stimulated plasma atrial natriuretic peptide concentrations and hemodynamics in conscious rats: effects of SCH 39.370, an endopeptidase inhibitor, and C-ANF-(4-23), a clearance receptor ligand. Kukkonen P; Vuolteenaho O; Ruskoaho H Endocrinology; 1992 Feb; 130(2):755-65. PubMed ID: 1531129 [TBL] [Abstract][Full Text] [Related]
14. SCH 34826: an overview of its profile as a neutral endopeptidase inhibitor and ANF potentiator. Sybertz EJ Clin Nephrol; 1991 Oct; 36(4):187-91. PubMed ID: 1835684 [TBL] [Abstract][Full Text] [Related]
15. Regional plasma levels of cardiac peptides and their response to acute neutral endopeptidase inhibition in man. Lainchbury JG; Nicholls MG; Espiner EA; Ikram H; Yandle TG; Richards AM Clin Sci (Lond); 1998 Nov; 95(5):547-55. PubMed ID: 9791040 [TBL] [Abstract][Full Text] [Related]
16. Effects of natriuretic peptides and neutral endopeptidase 24.11 inhibition in isolated perfused rat lung. Zhao L; Hughes JM; Winter RJ Am Rev Respir Dis; 1992 Nov; 146(5 Pt 1):1198-201. PubMed ID: 1443870 [TBL] [Abstract][Full Text] [Related]
17. The neutral endopeptidase-24.11 inhibitor SCH 34826 does not change opioid binding but reduces D1 dopamine receptors in rat brain. Trampus M; Ongini E; Varani K; Borea PA Eur J Pharmacol; 1991 Feb; 194(1):17-23. PubMed ID: 1647961 [TBL] [Abstract][Full Text] [Related]
18. Effects of neutral endopeptidase inhibition in the rat remnant kidney model. Jandeleit-Dahm K; Burrell LM; Kanazawa M; Casley D; Jackson B; Johnston CI Kidney Blood Press Res; 1998; 21(6):419-24. PubMed ID: 9933826 [TBL] [Abstract][Full Text] [Related]
19. Elevation of plasma atrial natriuretic peptide in rats with chronic heart failure by SCH 39370, a neutral metalloendopeptidase inhibitor. Tikkanen I; Helin K; Tikkanen T; Sybertz EJ; Vemulapalli S; Sariola H; Näveri H; Fyhrquist F J Pharmacol Exp Ther; 1990 Aug; 254(2):641-5. PubMed ID: 2143536 [TBL] [Abstract][Full Text] [Related]
20. Hemodynamic and hormonal effects of neutral endopeptidase inhibitor SCH 39370 in sheep. Charles CJ; Espiner EA; Cameron VA; Richards AM; Yandle TG; Sybertz EJ Hypertension; 1991 May; 17(5):643-51. PubMed ID: 1850715 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]